|Other Names||Bone morphogenetic protein 2, BMP-2, Bone morphogenetic protein 2A, BMP-2A, BMP2, BMP2A|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP1713a was selected from the N-term region of human Bmp2 . A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||The synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Induces cartilage and bone formation (PubMed:3201241). Stimulates the differentiation of myoblasts into osteoblasts via the EIF2AK3-EIF2A- ATF4 pathway. BMP2 activation of EIF2AK3 stimulates phosphorylation of EIF2A which leads to increased expression of ATF4 which plays a central role in osteoblast differentiation. In addition stimulates TMEM119, which upregulates the expression of ATF4 (PubMed:24362451).|
|Tissue Location||Particularly abundant in lung, spleen and colon and in low but significant levels in heart, brain, placenta, liver, skeletal muscle, kidney, pancreas, prostate, ovary and small intestine|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
BMP2 belongs to the transforming growth factor-beta (TGFB) superfamily. Bone morphogenic protein induces bone formation. BMP2 is a candidate gene for the autosomal dominant disease of fibrodysplasia (myositis) ossificans progressiva.
Lories, R.J., et al., Arthritis Rheum. 48(10):2807-2818 (2003).Maguer-Satta, V., et al., Exp. Cell Res. 282(2):110-120 (2003).Langenfeld, E.M., et al., Carcinogenesis 24(9):1445-1454 (2003).Dumont, N., et al., Biochem. Biophys. Res. Commun. 301(1):108-112 (2003).Hallahan, A.R., et al., Nat. Med. 9(8):1033-1038 (2003).
If you have any additional inquiries please email technical services at firstname.lastname@example.org.